Metraipolis › archive › dc_c8bf6cc3278e

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer — Europe PMC PMID:42350703

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42350703
DOI
10.1007/s10147-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-10-31T08:50:57.961Z
SHA-256 of the archived text
9724490473c339abce8f1102bcaf68fc8a5c0a7572813e0fe3b56c6656df3812
Stable URL of this page
https://metraipolis.com/documento/dc_c8bf6cc3278e

How to cite

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer — Europe PMC PMID:42350703 — Europe PMC (en), https://europepmc.org/article/MED/42350703 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c8bf6cc3278e (Metraipolis archive dc_c8bf6cc3278e, sha256 9724490473c339abce8f1102bcaf68fc8a5c0a7572813e0fe3b56c6656df3812)
BibTeX
@misc{dcc8bf6cc3278e,
  title = {Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer — Europe PMC PMID:42350703},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42350703},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c8bf6cc3278e; sha256 9724490473c339abce8f1102bcaf68fc8a5c0a7572813e0fe3b56c6656df3812},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42350703. Agents can read the archived copy with the MCP tool read_document.